Outcome Of Board Meeting Held On November 11, 2025 is attached
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mercury Laboratories Limited's Board approved unaudited financial results for Q2 and H1 FY26 (ended September 30, 2025). Revenue from operations for Q2 FY26 stood at ₹1,900.86 lakhs vs ₹1,819.40 lakhs in Q2 FY25, a modest ~4.5% YoY growth; H1 FY26 revenue was ₹3,714.40 lakhs vs ₹3,522.59 lakhs in H1 FY25. Net profit after tax surged to ₹164.33 lakhs in Q2 FY26 from just ₹50.04 lakhs in Q2 FY25 (over 3x jump), while H1 FY26 PAT rose to ₹261.09 lakhs from ₹157.20 lakhs (~66% growth). Profit before tax for H1 FY26 improved sharply to ₹466.17 lakhs from ₹157.20 lakhs a year ago. The statutory auditors issued an unqualified limited review report with no qualifications or emphasis of matter. Operating cash flow remained positive at ₹131.84 lakhs for H1 FY26, though lower than ₹167.61 lakhs in the prior-year period.
Strong PAT growth despite flat revenue suggests margin expansion, which is positive for shareholders. The clean auditor report and positive cash generation indicate financial health, though investors should watch whether the profit surge is sustainable or driven by one-off factors.